Kingfisher Capital’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Kingfisher Capital’s Portfolio BIS Stock Details BIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-3,697	Closed	-$1.36M	–	135
2014 Q4	$1.36M	Buy	+3,697	New	+$1.54M	0.7%	71

Other funds holding BIS

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

BAMS

Bellevue Asset Management (Switzerland) Kuesnacht, Switzerland $656M AUM 11.45% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FMA

FNY Managed Accounts New York $83.4M AUM 11.55% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Kingfisher Capital's BIS Position: Q1 2015 in Review

Kingfisher Capital sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q1 2015, closing a stake of 3,697 shares — an estimated $1.36M sold.

Kingfisher Capital first reported a position in BIS in Q4 2014 and held it in 1 quarter. The position peaked at $1.36M in Q4 2014. 13 funds tracked by Wall St. Rank hold BIS as of Q1 2015.

Kingfisher Capital reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q1 2015 after selling out during the quarter.
Kingfisher Capital sold 3,697 ProShares UltraShort NASDAQ Biotechnology shares in Q1 2015, an estimated $1.36M.
Kingfisher Capital first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q4 2014 and held it in 1 quarter.
Kingfisher Capital's ProShares UltraShort NASDAQ Biotechnology position peaked at $1.36M in Q4 2014.
13 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q1 2015.

Based on Kingfisher Capital's 13F filing for Q1 2015, filed 14 May 2015.